Author's response to reviews

Title: Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial

Authors:
Lajos Kemeny (kl@mail.dema.szote.u-szeged.hu)
Mario Amaya (drmarioamaya@gmail.com)
Petra Cetkovska (cetkovska@fnplzen.cz)
Natta Rajatanavin (natta.raj@mahidol.ac.th)
Woan-Rouh Lee (wrlee@tmu.edu.tw)
Annette Szumski (Annette.Szumski@pfizer.com)
Lisa Marshall (Lisa.Marshall2@pfizer.com)
Ehab Mahgoub (ehab.mahgoub@pfizer.com)
Emre Aldinc (emre.aldinc@pfizer.com)

Version: 2 Date: 13 April 2015

Author's response to reviews: see over
Dear Dr. Henderson,

On behalf of my co-authors and myself, I am hereby submitting our revised manuscript titled “Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial” for consideration to be published in *BMC Dermatology*. We have addressed the reviewers’ comments, the details of which are given below.

**Author's response to reviews**

**Title:** Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial

**Authors:**
L. Kemeny ([Kemeny.lajos@med.u-szeged.hu](mailto:Kemeny.lajos@med.u-szeged.hu))
M. Amaya ([drmarioamaya@gmail.com](mailto:drmarioamaya@gmail.com))
P. Cetkovska ([cetkovska@fnplzen.cz](mailto:cetkovska@fnplzen.cz))
N. Rajatanavin ([natta.raj@mahidol.ac.th](mailto:natta.raj@mahidol.ac.th))
W-R. Lee ([wrlee@tmu.edu.tw](mailto:wrlee@tmu.edu.tw))
A. Szumski ([Annette.Szumski@pfizer.com](mailto:Annette.Szumski@pfizer.com))
L. Marshall ([Lisa.Marshall2@pfizer.com](mailto:Lisa.Marshall2@pfizer.com))
E. Y. Mahgoub ([Ehab.A.Youseif@Pfizer.com](mailto:Ehab.A.Youseif@Pfizer.com))
E. Aldinc ([Emre.Aldinc@pfizer.com](mailto:Emre.Aldinc@pfizer.com))

**Version:** 2  **Date:** March 25, 2015

**Author's response to reviews**

**Reviewer's report**

**Title:** Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial

**Version:** 1  **Date:** 20 December 2014

**Reviewer:** Alexander A. Navarini

**Reviewer's report:**
The authors should show the ethnic composition of the QW/QW vs BIW/QC groups.

- We have included the data requested in Table 1.
The authors should at least show the ITT results in brackets beside the LOCF results.

- We believe there may be a misunderstanding of the data presented. The titles of Tables 4 and 5, and Figures 3 and 4 have been amended to address this issue. The results reported here are indeed for the ITT population; LOCF is the method used for imputing missing values for statistical analysis.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:** I declare that I have no competing interests

---

**Reviewer's report**

**Title:** Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial

**Version:** 1     **Date:** 28 February 2015

**Reviewer:** Yayoi Tada

**Reviewer's report:**

Kemeny et al. analyzed the effect of etanercept on different race. Although there are many studies regarding subset analysis with other biologics for psoriasis, this study provides some new information.

- We thank the reviewer for these comments.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:** I declare that I have no competing interests

---

We look forward to receiving your decision.

Sincerely,

Lajos Kemeny, MD